Total Payments
$695,273
2024 Payments
$103,300
Companies
29
Transactions
364
Medicare Patients
1,998
Medicare Billing
$94,447
Payment Breakdown by Category
Consulting$533,219 (76.7%)
Research$70,242 (10.1%)
Travel$47,648 (6.9%)
Other$35,595 (5.1%)
Food & Beverage$8,464 (1.2%)
Education$104.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $533,219 | 124 | 76.7% |
| Unspecified | $70,242 | 34 | 10.1% |
| Travel and Lodging | $47,648 | 77 | 6.9% |
| Honoraria | $28,631 | 9 | 4.1% |
| Food and Beverage | $8,464 | 116 | 1.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,764 | 1 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200 | 1 | 0.5% |
| Education | $104.20 | 2 | 0.0% |
Payments by Type
General
$625,031
330 transactions
Research
$70,242
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $123,135 | 60 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $65,194 | 40 | $0 (2024) |
| Janssen Research & Development, LLC | $57,635 | 38 | $0 (2020) |
| Novo Nordisk AS | $47,094 | 21 | $0 (2024) |
| Horizon Therapeutics plc | $46,074 | 15 | $0 (2023) |
| AGEPHA Pharma FZ LLC | $41,389 | 16 | $0 (2024) |
| PFIZER INC. | $41,301 | 14 | $0 (2024) |
| Amarin Pharma Inc. | $34,979 | 17 | $0 (2019) |
| Eli Lilly and Company | $30,411 | 23 | $0 (2024) |
| KOWA COMPANY, LTD. | $25,539 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $103,300 | 53 | AGEPHA Pharma FZ LLC ($41,389) |
| 2023 | $123,271 | 35 | PFIZER INC. ($26,392) |
| 2022 | $68,564 | 32 | CSL Behring ($25,210) |
| 2021 | $54,864 | 23 | Novo Nordisk AS ($19,500) |
| 2020 | $56,380 | 22 | CSL Behring ($17,940) |
| 2019 | $125,862 | 76 | Amarin Pharma Inc. ($34,979) |
| 2018 | $87,837 | 64 | Novartis Pharmaceuticals Corporation ($22,027) |
| 2017 | $75,195 | 59 | Janssen Research & Development, LLC ($29,559) |
All Payment Transactions
364 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $10,471.50 | General |
| 12/05/2024 | KOWA COMPANY, LTD. | — | — | Cash or cash equivalent | $302.50 | Research |
| Study: BAWH_KSI | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,270.00 | General |
| 11/16/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $3,293.75 | General |
| 09/19/2024 | KOWA COMPANY, LTD. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: BAWH_KSI | ||||||
| 09/13/2024 | CSL Behring | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | ||||||
| 09/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $545.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $4,266.71 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $3,408.00 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,108.60 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $944.08 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $846.20 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $720.36 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $422.08 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $360.55 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $336.00 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Travel and Lodging | Cash or cash equivalent | $108.81 | General |
| Category: Cardiovascular Diseases | ||||||
| 08/29/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $2,325.00 | General |
| 08/12/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 07/29/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $268.00 | General |
| 06/10/2024 | CSL Behring | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | ||||||
| 06/05/2024 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 05/27/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $545.00 | General |
| 05/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $545.00 | General |
| 05/14/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $72.16 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | CSL Behring | $50,000 | 18 |
| Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | CSL Behring | $12,000 | 4 |
| EX6018-4758 | Novo Nordisk AS | $3,000 | 1 |
| BAWH_KSI | KOWA COMPANY, LTD. | $2,303 | 2 |
| A CLINICAL OUTCOMES STUDY TO EVALUATE THE EFFECTS OF IL-6 RECEPTOR BLOCKADE WITH TOCILIZUMAB TCZ IN COMPARISON WITH ETANERCEPT ETA ON THE RATE OF CARDIOVASCULAR EVENTS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS RA. | F. Hoffmann-La Roche AG | $664.79 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 528 | 531 | $131,448 | $23,793 |
| 2022 | 5 | 541 | 545 | $130,633 | $24,079 |
| 2021 | 5 | 513 | 521 | $128,952 | $24,705 |
| 2020 | 4 | 416 | 420 | $108,147 | $21,870 |
Total Patients
1,998
Total Services
2,017
Medicare Billing
$94,447
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 259 | 261 | $74,593 | $13,693 | 18.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 120 | 120 | $49,329 | $8,622 | 17.5% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 57 | 58 | $2,824 | $560.86 | 19.9% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 24 | 24 | $2,472 | $490.49 | 19.8% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 18 | 18 | $1,140 | $213.49 | 18.7% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 26 | 26 | $758.00 | $152.50 | 20.1% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 24 | 24 | $332.00 | $60.52 | 18.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 266 | 266 | $78,806 | $14,637 | 18.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 80 | 81 | $41,836 | $7,410 | 17.7% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 38 | 38 | $3,824 | $777.72 | 20.3% |
| 93356 | Heart muscle strain imaging | Facility | 2022 | 76 | 77 | $3,718 | $750.02 | 20.2% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2022 | 35 | 35 | $987.00 | $210.31 | 21.3% |
| 93356 | Heart muscle strain imaging | Office | 2022 | 11 | 12 | $958.00 | $201.34 | 21.0% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2022 | 35 | 36 | $504.00 | $93.35 | 18.5% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 302 | 304 | $91,200 | $17,386 | 19.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 70 | 73 | $30,492 | $5,802 | 19.0% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2021 | 37 | 38 | $3,925 | $815.11 | 20.8% |
| 93356 | Heart muscle strain imaging | Facility | 2021 | 39 | 39 | $1,891 | $410.28 | 21.7% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2021 | 32 | 33 | $968.00 | $201.60 | 20.8% |
| 93325 | Doppler ultrasound study of color-directed heart blood flow, rate, and valve function | Facility | 2021 | 33 | 34 | $476.00 | $89.76 | 18.9% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2020 | 259 | 263 | $77,724 | $15,713 | 20.2% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 51 | 51 | $25,114 | $5,020 | 20.0% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2020 | 37 | 37 | $3,831 | $822.80 | 21.5% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2020 | 32 | 32 | $960.00 | $210.16 | 21.9% |
| 93325 | Doppler ultrasound study of color-directed heart blood flow, rate, and valve function | Facility | 2020 | 37 | 37 | $518.00 | $104.11 | 20.1% |
About Dr. Paul Ridker, MD
Dr. Paul Ridker, MD is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063478261.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Ridker, MD has received a total of $695,273 in payments from pharmaceutical and medical device companies, with $103,300 received in 2024. These payments were reported across 364 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($533,219).
As a Medicare-enrolled provider, Ridker has provided services to 1,998 Medicare beneficiaries, totaling 2,017 services with total Medicare billing of $94,447. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Boston, MA
- Active Since 04/25/2006
- Last Updated 07/19/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1063478261
Products in Payments
- LODOCO (Drug) $41,389
- KRYSTEXXA (Biological) $39,742
- EPANOVA (Drug) $35,586
- Vascepa (Drug) $34,979
- ILARIS (Biological) $17,962
- PRALUENT (Drug) $14,828
- XPHOZAH 30 MG (Drug) $13,600
- SOTAGLIFLOZIN (Drug) $13,169
- NO PRODUCT DISCUSSED (Drug) $11,826
- Victoza (Drug) $11,330
- Belviq (Drug) $8,047
- ACZ885M (Biological) $6,979
- TEPEZZA (Drug) $6,446
- NEXLIZET (Drug) $4,420
- CRESTOR (Drug) $4,296
- ENTRESTO (Drug) $3,999
- K-877 (Drug) $2,396
- NEXLETOL (Drug) $1,227
- Actemra (Biological) $664.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Christopher Cannon, Md, MD
Cardiovascular Disease — Payments: $869,405
Cardiovascular Disease $869,405